- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05540860
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (LYNX)
A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The EDG-5506-210 protocol was amended to include an additional dose cohort and a cohort to include participants not currently treated with corticosteroids.
This is a 2-part, multi-center, Phase 2 study to evaluate the effect of EDG-5506 on safety, pharmacokinetics and biomarkers of muscle damage in approximately 54 children with DMD treated with oral, once-daily EDG-5506 for 24 months. This study will have up to a 4-week Screening period, a 12-week randomized, double-blind, placebo controlled treatment period (Part A), a 92-week open-label extension period (Part B), and a 2-week follow up period.
Approximately 54 participants aged 4 to 9 years inclusive will be randomized to EDG-5506 or placebo in a 2:1 ratio. Five dose cohorts (C1, C2, C3, C4 and C5) of approximately 9 participants each will be enrolled sequentially.
An additional cohort, Cohort 2NS, to include participants (aged 4 to 7 years inclusive) not currently treated with corticosteroids, will enroll approximately 9 participants after Cohort 2 safety review and in parallel with the additional cohorts.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Edgewise Therapeutics
- Phone Number: 720-262-7002
- Email: studies@edgewisetx.com
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Recruiting
- Arkansas Children's Hospital
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Medical Center
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Recruiting
- Rare Disease Research
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- University of Kansas Medical Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Recruiting
- Kennedy Krieger Institute
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- Recruiting
- University of Massachusetts Memorial Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital
-
Columbus, Ohio, United States, 43205
- Recruiting
- Nationwide Children's Hospital
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Recruiting
- Cook Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Common Inclusion Criteria:
- A documented mutation on the DMD gene and phenotype consistent with Duchenne muscular dystrophy.
- Able to complete the stand from supine in ≤ 10 seconds and able to perform the 4-stair climb in < 10 seconds at the Screening visit.
- Body weight greater than or equal to 15 kg and less than 35 kg at the Screening visit.
For Cohorts 1, 2, 3, 4 and 5:
Aged 4-9 years on a stable dose of corticosteroids for a minimum of 6 months prior to the Baseline visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Aged 4-7 years not on corticosteroids within 6 months prior to the Baseline visit.
Key Common Exclusion Criteria:
- Medical history or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood testing.
- A forced vital capacity < 60% predicted at the Screening visit for those participants who are > 8 years old at Screening.
- A cardiac echocardiography showing left ventricular ejection < 45% at the Screening visit.
- Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
- Receipt of a stable dose of an approved exon-skipping therapy with a treatment duration of less than 1 year prior to the Screening visit.
For Cohort 2 Non-Steroid (Cohort 2NS):
Receipt of oral corticosteroids for the treatment of Duchenne muscular dystrophy in the previous 6 months. Participants will not be tapered off steroids for the purpose of this study and oral corticosteroids for the treatment of Duchenne muscular dystrophy may be initiated after the Week 16 visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Drug: EDG-5506 Drug: Placebo
|
EDG-5506 is administered orally once per day
Placebo is administered orally once per day
|
Experimental: Cohort 2
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
Experimental: Cohort 3
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
Experimental: Cohort 4
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
Experimental: Cohort 2NS
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
Experimental: Cohort 5
Drug: EDG-5506 Drug: Placebo
|
Placebo is administered orally once per day
EDG-5506 is administered orally once per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events during treatment with EDG-5506 or placebo
Time Frame: 24 months
|
All participants
|
24 months
|
Severity of adverse events during treatment with EDG-5506 or placebo
Time Frame: 24 months
|
All participants
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in serum creatinine kinase
Time Frame: 12 weeks
|
All participants
|
12 weeks
|
Change from Baseline in fast skeletal muscle troponin I
Time Frame: 12 weeks
|
All participants
|
12 weeks
|
Incidence of abnormal clinical chemistry test results
Time Frame: 24 months
|
All participants
|
24 months
|
Incidence of abnormal hematology test results
Time Frame: 24 months
|
All participants
|
24 months
|
Incidence of abnormal coagulation test results
Time Frame: 24 months
|
All participants
|
24 months
|
Incidence of abnormal urinalysis test results
Time Frame: 24 months
|
All participants
|
24 months
|
Pharmacokinetics as measured by steady state plasma concentration
Time Frame: 24 months
|
All participants
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Sam Collins, MBBS, PhD, Edgewise Therapeutics, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDG-5506-210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on EDG-5506 Dose 1
-
Edgewise Therapeutics, Inc.RecruitingDuchenne Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.CompletedNervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Healthy VolunteerUnited States
-
Edgewise Therapeutics, Inc.Medpace, Inc.Enrolling by invitationBecker Muscular DystrophyUnited States, Netherlands
-
Edgewise Therapeutics, Inc.Medpace, Inc.; SYSNAV; ImagingNMDRecruitingBecker Muscular DystrophyUnited States, Netherlands, United Kingdom
-
Edgewise Therapeutics, Inc.Medpace, Inc.CompletedBecker Muscular DystrophyUnited States
-
Edgewise Therapeutics, Inc.CompletedMuscular DystrophiesUnited States
-
Edgewise Therapeutics, Inc.Worldwide Clinical TrialsCompletedBecker Muscular Dystrophy | Healthy VolunteerUnited States
-
Medy-ToxCompletedLateral Canthal Lines | Glabellar LinesUnited States, Russian Federation, Germany, Canada, Belgium, United Kingdom
-
Zensun Sci. & Tech. Co., Ltd.Zensun USA Inc.CompletedChronic Heart FailureUnited States
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France